Related Experiment Video

Updated: Jun 6, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K

Double-Faced Immunological Effects of CDK4/6 Inhibitors on Cancer Treatment: Challenges and Perspectives

Yongqin Liu1,2, Yiying Deng1,2, Chang Yang1,2

  • 1Department of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.

Bioengineering (Basel, Switzerland)
|November 27, 2024
PubMed

Insights

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) treat breast cancer by affecting cell division and the immune system. Understanding these dual roles is key to overcoming drug resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Cyclin-dependent kinases (CDKs) regulate cell cycle progression.
  • Abnormal CDK activation drives cancer cell proliferation and tumorigenesis.
  • CDK4/6 inhibitors (CDK4/6is) are approved for HR+/HER2- metastatic breast cancer.

Purpose of the Study:

  • To review the paradoxical immunological effects of CDK4/6 inhibitors in cancer treatment.
  • To elucidate anticancer mechanisms involving immunomodulatory activity.
  • To explore how CDK4/6is induce acquired drug resistance by altering the immune microenvironment.

Main Methods:

  • Comprehensive literature review of CDK4/6 inhibitors and their immunological effects.
  • Analysis of clinical data on CDK4/6 inhibitor-induced immune system changes.
  • Discussion of molecular mechanisms underlying CDK4/6 inhibitor-mediated immunomodulation and resistance.

Main Results:

  • CDK4/6is exhibit dual roles: promoting cell-cycle arrest and altering the immune system for antitumor effects.
  • Immune system modulation by CDK4/6is can paradoxically lead to acquired drug resistance.
  • Dysregulation of the tumor immune microenvironment is implicated in resistance to CDK4/6 inhibitors.

Conclusions:

  • CDK4/6is have significant immunomodulatory activities with implications for cancer therapy.
  • Understanding the complex interplay between CDK4/6is and the immune system is crucial for optimizing treatment strategies.
  • Combining CDK4/6is with immunotherapy presents a promising approach to overcome drug resistance.
Keywords:
CDK4/6 inhibitordrug resistanceimmune microenvironmentimmunomodulatory effectimmunotherapy

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

296

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K